HC Wainwright Reiterates $31.00 Price Target for MediWound (NASDAQ:MDWD)

MediWound (NASDAQ:MDWD) has been assigned a $31.00 price target by investment analysts at HC Wainwright in a research report issued to clients and investors on Thursday, MarketBeat reports. The firm currently has a “buy” rating on the biopharmaceutical company’s stock. HC Wainwright’s price objective suggests a potential upside of 52.41% from the company’s previous close.

A number of other research analysts have also recently commented on the company. Wall Street Zen upgraded MediWound to a “sell” rating in a research note on Friday, March 21st. Alliance Global Partners initiated coverage on shares of MediWound in a research note on Friday, May 2nd. They set a “buy” rating and a $25.00 price objective on the stock. Finally, Craig Hallum initiated coverage on shares of MediWound in a report on Friday, February 28th. They set a “buy” rating and a $39.00 target price for the company. One investment analyst has rated the stock with a sell rating and four have assigned a buy rating to the stock. According to data from MarketBeat.com, MediWound has an average rating of “Moderate Buy” and a consensus target price of $31.25.

MediWound Stock Performance

NASDAQ MDWD opened at $20.34 on Thursday. MediWound has a fifty-two week low of $12.78 and a fifty-two week high of $24.00. The stock has a market cap of $219.83 million, a P/E ratio of -7.01 and a beta of 0.30. The stock has a 50 day simple moving average of $17.44 and a two-hundred day simple moving average of $17.61.

MediWound (NASDAQ:MDWD) last issued its quarterly earnings data on Wednesday, May 21st. The biopharmaceutical company reported ($0.07) EPS for the quarter, topping the consensus estimate of ($0.65) by $0.58. MediWound had a negative net margin of 142.29% and a negative return on equity of 82.17%. The business had revenue of $3.96 million during the quarter, compared to analyst estimates of $5.20 million. During the same period in the prior year, the business earned ($1.05) EPS. Sell-side analysts predict that MediWound will post -2.66 earnings per share for the current year.

Institutional Investors Weigh In On MediWound

Institutional investors and hedge funds have recently made changes to their positions in the company. Yelin Lapidot Holdings Management Ltd. increased its holdings in shares of MediWound by 13.4% in the 4th quarter. Yelin Lapidot Holdings Management Ltd. now owns 851,361 shares of the biopharmaceutical company’s stock worth $15,154,000 after purchasing an additional 100,618 shares in the last quarter. Northern Trust Corp boosted its position in shares of MediWound by 94.6% during the fourth quarter. Northern Trust Corp now owns 144,768 shares of the biopharmaceutical company’s stock valued at $2,577,000 after buying an additional 70,367 shares during the last quarter. Essex Investment Management Co. LLC increased its holdings in MediWound by 30.7% in the 4th quarter. Essex Investment Management Co. LLC now owns 148,949 shares of the biopharmaceutical company’s stock worth $2,651,000 after buying an additional 35,012 shares in the last quarter. MGO One Seven LLC purchased a new position in MediWound in the 4th quarter worth about $216,000. Finally, Silverberg Bernstein Capital Management LLC lifted its stake in MediWound by 13.1% during the 1st quarter. Silverberg Bernstein Capital Management LLC now owns 103,944 shares of the biopharmaceutical company’s stock valued at $1,613,000 after acquiring an additional 12,060 shares during the period. Institutional investors own 46.83% of the company’s stock.

MediWound Company Profile

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units.